Cell and Gene Therapies

Insights on delivering cell and gene clinical trials in multiple therapeutic areas based on lessons learned and best practices

Approaching the CAR T-cell therapy horizon

Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers, but further innovations are needed before the technology can reach its full potential. In this whitepaper, we explore the most exciting clinical developments in CAR T-cell therapy, and relate them to limitations of approved therapies. 

Read the whitepaper

Mainstreaming Cell and Gene Therapies

The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases.

Read the whitepaper

Long-term follow-up studies of cell and gene therapies

Regulators typically expect that Sponsors collect up to 15 years of follow-up data on patients who’ve received cell and gene therapies either through a clinical trial or in clinical practice.

Read the whitepaper

The affordability hurdle for gene therapies

Until now US payers have absorbed and managed the cost of ultra-expensive therapies, but how long can they continue to do so? Read our whitepaper to understand the payer perspective on advanced therapy medicinal products.

Read the whitepaper

The promise and complexity of living therapies

As development of cell and gene therapies (CGT) accelerates, so will the demand for best practices, and better tools and solutions. For advanced therapies, the product and patient journey is entirely different from traditional trials. As such, biotech and pharma companies will need to overcome challenges and complexities from regulatory pathways and patient recruitment to logistics and manufacturing. Adopting strategic partnerships with deep CGT expertise with a broad spectrum of solutions and services is vital to the success of a development programme.

Read the eBook

Enabling clinical development of Cell and Gene Therapies on a global basis

ICON's CGT team share insights on best practices, custom resources and innovative tools for enabling clinical development of cell and gene therapies on a global basis in this BioInsights podcast (40 mins).

Download the full transcript here.

Listen to podcast

Cell and Gene Therapy blogs and media contributions

Receive more insights on cell and gene therapies from ICON

Please visit ICON's Preference Centre and select 'Cell and Gene Therapies' under 'Therapeutic Areas of Interest' to receive new insights on cell and gene therapies.

Receive new insights

Cell and Gene Therapies at ICON

ICON’s Cell and Gene Therapy (CGT) Solution was designed to expedite every aspect of a cell therapy clinical trial and address specific needs of CGT product development. The CGT Leadership Team leads your trials with innovative technologies and standardised tools for CGT trial execution, management of high data volumes, and extensive team and site training. Read more about ICON's services.


Read more about ICON's services in cell and gene therapies